| REVIEW ARTICLE |
|
| Year : 2015 | Volume
: 25
| Issue : 3 | Page : 129-132 |
Percutaneous native kidney biopsy in patients receiving antiplatelet agents- is it necessary to stop them routinely?
S Nayak-Rao
Consultant Nephrologist, Sri Krishna Sevashrama Hospital, Bengaluru, Karnataka, India
Correspondence Address:
S Nayak-Rao
Sri Krishna Sevashrama Hospital, 45th Cross, Jayanagar, 5th Block, Bengaluru - 560 082, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0971-4065.147374
Percutaneous renal biopsy plays an important role in the investigational approach of the nephrologist. Though the technique and the safety of the procedure has improved over the last two decades it remains an invasive procedure and can be associated with bleeding complications. To minimize the risk of bleeding, it has been the practice of many centers and nephrologists to advise patients receiving antiplatelet agents to discontinue them 5-7 days before planned procedure. This advice is based on opinion and pre-established procedure or norms rather than sound evidence based guidelines. This article aims to be a critical appraisal of this unnecessary and sometimes not so safe practice of routine stoppage of antiplatelet agents prior to kidney biopsy.
[FULL TEXT] [PDF]*
|
|
Editorial Board
